Nelly Robillard

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre et al. · Blood · 2018 · 420 citations · Full text

Medicine, Hematology, Oncology +15

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival

Soraya Wuillème‐Toumi, Nelly Robillard, P Gomez et al. · Leukemia · 2005 · 338 citations

Medicine, Cell Biology, Oncology +13

Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal Allografts

Jean-Paul Soulillou, Diego Cantarovich, Brigitte Le Mauff et al. · New England Journal of Medicine · 1990 · 274 citations · Full text

Life Sciences, Immunology, Nephrology +17

Contrasting CD25hiCD4+T Cells/FOXP3 Patterns in Chronic Rejection and Operational Drug-Free Tolerance

St phanie Louis, Cécile Braudeau, Magali Giral et al. · Transplantation · 2006 · 272 citations

Life Sciences, Immunology, Nephrology +17

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

Murielle Roussel, Valérie Lauwers‐Cancès, Nelly Robillard et al. · Journal of Clinical Oncology · 2014 · 265 citations · Full text

Medicine, Oncology, Pharmacotherapy +14